Sarepta Therapeutics stock is coming off a long period of weak share price performance, with a steep decline over the past three years sitting alongside a mixed valuation profile and fresh regulatory progress that could influence how investors think about what the shares are worth today.

• Over the past three years, Sarepta Therapeutics has fallen 83.7%, which places the current valuation in the context of a prolonged drawdown rather than a recent rally.
• The FDA’s acceptance of supplemental applications to convert key Duchenne muscular dystrophy therapies to traditional approval may support confidence in Sarepta Therapeutics’ revenue durability, while any future regulatory or clinical setbacks remain a central risk to the stock’s valuation.
• On Simply Wall St’s broader checks, Sarepta Therapeutics scores 3 out of 6 on valuation, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Sarepta Therapeutics’ current share price already reflects the regulatory progress and recovery in shorter term returns, or if the long three year decline still leaves room for a more constructive valuation case.

Is Sarepta Therapeutics Getting Expensive on Earnings?

The P/E ratio is a useful cross check for Sarepta Therapeutics because it anchors the stock to the earnings it is already producing. Sarepta trades at about 27.9x earnings, which sits above the Biotechs industry average of roughly 17.3x but below the peer group average of about 36.9x. That mix suggests investors are paying more than the typical biotech stock per dollar of earnings, while not assigning the same multiple as some closer peers.

The Fair Ratio model points to a P/E of around 5.2x for Sarepta, and the large gap to the current 27.9x indicates the framework is heavily discounting the company for its risk profile and earnings quality rather than offering a precise target. Despite the recent lift in Sarepta Therapeutics shares after the FDA accepted supplemental applications for its Duchenne therapies, the stock still screens as expensive on this earnings based lens.

On this P/E measure, Sarepta Therapeutics stock screens as expensive relative to this framework.

The Sarepta Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take Sarepta Therapeutics' valuation puzzle a step further by spelling out what kind of future growth, margins and earnings would need to occur for the stock to be worth meaningfully more or less than it trades for today, and they sit on the company’s Community page. Rather than relying on a single multiple or model, each narrative sets out its own fair value assumptions so you can compare them with actual results over time.

Community views on Sarepta Therapeutics sit at opposite ends of the spectrum, with one camp seeing reset upside and the other focused on execution and regulatory risk.

Bull case: 20% undervalued

"Development and commercialization of other programs like the LGMD and siRNA platforms represent additional revenue streams, positively impacting overall financial health..."

Bear case: 145% overvalued

"Overreliance on key products, delayed capacity expansion, and high upfront investments heighten risks of market saturation, revenue concentration, and sustained operating losses..."

Do you think there's more to the story for Sarepta Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Sarepta Therapeutics, the current setup leans toward overvalued on earnings, with a clear gap between the Fair Ratio model and where the stock trades today. That reflects a market willing to pay up for its Duchenne muscular dystrophy portfolio, while the framework heavily penalises execution, regulatory and earnings quality risk. The crux for investors is whether Sarepta can translate its regulatory progress into durable, higher quality earnings that make today’s richer multiple feel justified rather than stretched.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.